Which Vaccine Stock is a Better Buy? By StockNews
[ad_1]
With more than 90% efficacy, BioNTech SE (NASDAQ:) and Moderna , Inc’s (NASDAQ:) COVID-19 vaccines have gained the majority of market share and revenues have boomed. Which stock is better to buy right now? Find out more. BioNTech SE, (BNTX), develops and sells immunotherapies against cancer and infectious diseases. Moderna (MRNA), on the other hand develops vaccines and therapeutics that use messenger RNA. This is used to treat rare and serious diseases as well as immuno-oncology and cardiovascular disease.
Because of large capital inflows for developing a vaccine effective to stop the spread, the biotech industry flourished. Companies that developed a vaccine, and received approval to commercialize it, saw significant profits.
While COVID-19 is still a problem, it’s expected that the industry will remain prominent. Also, the industry’s focus on developing personalized medicines and immunotherapy is expected to be a major trend shaping the industry’s growth in the near term. Through 2027, the U.S. market for biotechnology is expected to expand at an annual CAGR of more than 9.2%. MRNA and BNTX, which are both market leaders, will benefit from industry tailwinds.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]